Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469368 | 1.00 | KMT2A (0.54) | KMT2AEPHX2PTPRCMALT1TDP1 | |
| Hydrochloric Acid SCHEMBL455447 | 0.99 | KMT2A (0.53) | KMT2AEPHX2PTPRCMALT1TDP1 | |
| SCHEMBL29616475 | 0.91 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3 | |
| SCHEMBL19931854 | 0.91 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3 | |
| SCHEMBL13247459 | 0.90 | KMT2A (0.57) | KMT2AEPHX2MALT1CASP3 | |
| SCHEMBL30678165 | 0.90 | KMT2A (0.57) | KMT2AEPHX2MALT1CASP3 | |
| SCHEMBL1007491 | 0.88 | KMT2A (0.58) | KMT2AEPHX2CASP3 | |
| SCHEMBL5557644 | 0.88 | KMT2A (0.60) | KMT2AEPHX2MALT1CASP3 | |
| Hydrochloric Acid SCHEMBL7876414 | 0.87 | KMT2A (0.57) | KMT2AEPHX2CASP3 | |
| SCHEMBL26172640 | 0.87 | KMT2A (0.60) | KMT2AEPHX2MALT1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12478617-B2 | Lipidated peptide inhibitors of interleukin-23 receptor | JANSSEN BIOTECH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240173309-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-30 | — | — | US | disclosed |
| WO-2023288019-A2 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173309-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | KMT2A 3658/4885EPHX2 2196/4885PTPRC 505/4885 |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL36G, IL15RA | KMT2A 3239/4885EPHX2 2337/4885PTPRC 1467/4885 |
| US-12478617-B2 | Lipidated peptide inhibitors of interleukin-23 receptor | IL23R, IL1RN, IL36G | KMT2A 3658/4885EPHX2 2196/4885PTPRC 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.